Recent advances have unraveled molecular and cellular mechanisms regulating the interaction between microenvironmental components and tumor epithelia leading to a new era of personalized therapies. The approvals of a variety of immunotherapies including anti-PD1/PD-L1 highlight the promise of further understanding these mechanisms. Despite these developments, such therapies have shown limited applicability in tumors of the gastrointestinal tract. For instance, immunotherapies such as anti-PD1 are only effective in a small portion of colorectal cancers with high microsatellite instability. This exemplifies the pressing need to better understand molecular and cellular factors influencing the tumor microenvironment and consequently the response to therapy.
Declarations:
1. NW is a patent holder for a DCLK1 monoclonal antibody US9663585B2
2. DQ is a patent holder for a DCLK1 monoclonal antibody US9663585B2
Recent advances have unraveled molecular and cellular mechanisms regulating the interaction between microenvironmental components and tumor epithelia leading to a new era of personalized therapies. The approvals of a variety of immunotherapies including anti-PD1/PD-L1 highlight the promise of further understanding these mechanisms. Despite these developments, such therapies have shown limited applicability in tumors of the gastrointestinal tract. For instance, immunotherapies such as anti-PD1 are only effective in a small portion of colorectal cancers with high microsatellite instability. This exemplifies the pressing need to better understand molecular and cellular factors influencing the tumor microenvironment and consequently the response to therapy.
Declarations:
1. NW is a patent holder for a DCLK1 monoclonal antibody US9663585B2
2. DQ is a patent holder for a DCLK1 monoclonal antibody US9663585B2